Bevacizumab, Docetaxel, and Radiation Therapy in Treating Patients With Stage III or Stage IV Head and Neck Cancer

You may be eligible if

• DISEASE CHARACTERISTICS:
• Histologically or cytologically confirmed squamous cell carcinoma of the head and neck
• * Stage III or IV disease
• * No evidence of distant metastases
• * No salivary gland or paranasal sinus squamous cell carcinoma
• No disease with close proximity to a major vessel
• Measurable disease
• No known CNS or brain metastases
• * Patients with intracranial extension without cerebral involvement may be eligible
• PATIENT CHARACTERISTICS:
• ECOG performance status 0-1
• Life expectancy \> 12 weeks
• Absolute neutrophil count ≥ 1,500/mm\^3
• Platelet count ≥ 100,000/mm\^3
• Hemoglobin ≥ 10 g/dL
• Bilirubin normal
• AST and ALT ≤ 2 times upper limit of normal
• PT normal
• Creatinine normal OR
• Creatinine clearance ≥ 60 mL/min
• Urine protein: creatinine ratio \< 1.0
• No bleeding diathesis or coagulopathy
• Not pregnant or nursing
• Negative pregnancy test
• Fertile patients must use effective contraception
• No history of allergic reaction attributed to compounds of similar chemical or biological composition to study drugs
• No pre-existing peripheral neuropathy ≥ grade 2
• No ongoing or active infection
• No serious non-healing wound, ulcer, or bone fracture
• No New York Heart Association class II-IV congestive heart failure
• No significant arrhythmias requiring medication
• No myocardial infarction within the past 6 months
• No stroke within the past 6 months
• No symptomatic coronary artery disease
• No second- or third-degree heart block or bundle branch block
• No unstable angina pectoris
• No hypertension (i.e., blood pressure ≥ 150/100 mm Hg)
• No other clinically significant heart disease
• No significant traumatic injury within the past 4 weeks
• No psychiatric illness or social situation that would preclude study compliance
• No HIV positivity
• No other malignancy within the past 5 years except squamous cell or basal cell skin cancer or carcinoma in situ of the cervix
• No other uncontrolled illness
• No poorly compliant patients
• PRIOR CONCURRENT THERAPY:
• No prior chemotherapy or radiotherapy
• No prior investigational anticancer agents
• More than 4 weeks since prior major surgery
• More than 1 week since prior minor surgery, fine-needle aspiration, or core needle biopsy
• No concurrent major surgery except planned neck dissection
• No concurrent routine colony-stimulating factor therapy
• No other concurrent investigational agents
• No other concurrent anticancer therapy